Pune, Jan. 10, 2023 (GLOBE NEWSWIRE) -- According to a new market research report titled, “Human Microbiome Market by Product (Probiotics, Prebiotics, Symbiotics, Medical Food, Drugs and Others), by Disease (Obesity, Diabetes, Autoimmune Disorders, Cancer, C. difficile Infection, Gastrointestinal Disorders, Central Nervous System Disorders and Others), by Application (Therapeutics and Diagnostics) – Global Outlook & Forecast 2022-2030" published by Growth Plus Reports, the Human Microbiome Market is expected to grow at a CAGR of 25% from 2021 to reach US$ 442.37 billion by 2030.
Download PDF Brochure of Human Microbiome Market Size - COVID-19 Impact and Global Analysis with Strategic Developments at:
https://growthplusreports.com/inquiry/request-sample/human-microbiome-market/7940
Market Drivers
One of the main reasons driving the market growth is the rising prevalence of chronic lifestyle illnesses and infections caused by microbial dysbiosis worldwide. Additionally, the ageing population, which is more vulnerable to these diseases, is driving market expansion. The market's expansion can also be attributable to the increased focus on creating medicines for the human microbiome that are more effective. In order to effectively treat a variety of gastrointestinal disorders, the human gut microbiota is being cultivated in precise combinations. In keeping with this, the start of the coronavirus (COVID-19) pandemic is also boosting market expansion. In order to evaluate the severity of the illnesses and create the necessary treatments and vaccinations, researchers are deeply examining the lung microbiomes.
Excerpts from ‘By Application Segmentation’
Based on application, the global human microbiome market has been segmented into:
- Therapeutics
- Diagnostics
The therapeutics segment dominated the market during forecast period and will continue to dominate through the forecasted period. In the treatment of COVID-19, IBD, C. difficile infections, Crohn's disease, and diabetes, microbiome therapies have a wide range of uses. The rise is anticipated to be accelerated by increased research efforts being made by research institutions to identify further medicinal uses for the human microbiome. For instance, the University of Zurich examined the microbiome in COVID-19 patients in 2020 for potential future therapeutic and preventive measures (MICRO-COV). Positive findings from these research investigations will widen the segment under study's options for expansion. Human gastrointestinal microbiome research can contribute significantly to clinical and therapeutic development if it moves toward mechanistic studies, according to an article in the Frontiers in Microbiology Journal titled "Key Technologies for Progressing Discovery of Microbiome-Based Medicines" that was published in June 2021. Additionally, it was suggested that establishing causal relationships between the microbiome and disease is necessary for the development of more effective and targeted treatments. Future development will depend on strong collaborations between cutting-edge sequencing techniques, computational analyses, and experimental assays. The market expands as a result of these research.
Excerpts from ‘By Region Segmentation’
Based on region, the global human microbiome market has been segmented into:
- North America
- Europe
- Asia Pacific
- Rest Of The World
Due to the increasing prevalence of autoimmune disorders and diseases linked to a sedentary lifestyle in these areas, North America presently controls the majority of the global market for the human microbiome. The extremely profitable growth can also be ascribed to a solid medication pipeline. For instance, in 2019, the phase-III of clinical trials for Seres Therapeutics' stool-derived therapy for recurrent Clostridium difficile infection was successful. To take advantage of the communities of microorganisms that live inside human bodies, Stanford ChEM-H and the Department of Bioengineering together created the Stanford Microbiome Therapies Initiative (MITI) in August 2019. The National Institutes of Health (NIH) support the microbiome initiative, with 21 out of 27 NIH institutes supporting and funding this field through extramural projects, according to an article in BioMed Central Journal, 2019. Additionally, the Canadian government committed an expenditure of USD 18 million in microbiome research in 2019. With the help of this investment, seven research teams from all around the nation may be able to better understand how the microbiome affects conditions including diabetes, inflammatory bowel disease in children, foetal malnutrition, and childhood asthma. As a result, the human microbiome market in North America has become one of the leading markets and is expanding at a healthy rate because to these research activities and increased government support.
Excerpts from ‘Competitive Landscape’
Some of the prominent players in the global human microbiome market include:
- Obiome
- Enterome Biosciences SA
- 4D Pharma
- Metabiomics Corp. (Biospherex LLC)
- Microbiome Therapeutics LLC
- Osel, Inc.
- Rebiotix, Inc.
- Vedanta Biosciences
- Second Genome
- Seres Therapeutics
- Synthetic Biologics, Inc.
- Ferring Pharmaceuticals
Browse Detailed Summary of Research Report with TOC:
https://growthplusreports.com/report/human-microbiome-market/7940
Table of Content
- INTRODUCTION
- Market Ecosystem
- Timeline Under Consideration
- Historical Years - 2020
- Base Years - 2021
- Forecasted Years – 2022 to 2030
- Currency Used in the Report
- RESEARCH METHODOLOGY
- Research Approach
- Data Collection Methodology
- Data Sources
- Secondary Sources
- Primary Sources
- Market Estimation Approach
- Bottom Up
- Top Down
- Market Forecasting Model
- Limitations and Assumptions
- PREMIUM INSIGHTS
- Current Market Trend (COVID-19 Perspective)
- Key Players & Competitive Positioning (2021)
- MARKET DYNAMICS
- Drivers
- Restraints/Challenges
- Opportunities
- GLOBAL HUMAN MICROBIOMEMARKET - ANALYSIS & FORECAST, BY PRODUCT
- Probiotics
- Prebiotics
- Symbiotics
- Medical Food
- Diseases
- Others
- GLOBAL HUMAN MICROBIOMEMARKET - ANALYSIS & FORECAST, BY DISEASE
- Obesity
- Diabetes
- Autoimmune Disorders
- Cancer
- C. difficile Infection
- Gastrointestinal Disorders
- Central Nervous System Disorders
- Others
Scope of the Report:
| Report Attribute | Details |
| Market size value in 2021 | US$ 59.37 billion |
| Revenue forecast in 2030 | US$ 442.37 billion |
| Growth Rate | CAGR of 25% from 2022 to 2030 |
| Base year for estimation | 2021 |
| Forecast period | 2022-2030 |
| Segments covered | by product, disease, application, and region. |
| Regional scope | North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
VALUE PROPOSITIONS RELATED TO THE REPORT:
- Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
- Comprehensive quantitative and qualitative insights at segment and sub-segment level
- Covid 19 impact trends and perspective
- Granular insights at global/regional/country level
- Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
- Blanket coverage on competitive landscape
- Winning imperatives
- Exhaustive coverage on 'Strategic Developments' registered by leading players of the market
CUSTOMIZATION OPTIONS:
- Distributor Landscape Assessment
- Pipeline Assessment
- Pricing Intelligence
- Customer Base Assessment
- Investment & Initiatives Analysis
- 'Business Profile' of Key Players
Directly Purchase Premium Copy of Human Microbiome Market Growth Report (2022-2030) at:
About Us
Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).
Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis, and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.
We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.
